NRS
CLIN
Kathryn McAndrews, APRN
Pulmonary
Rush University Medical Center
Jonathan Cogen, MD MPH (he/him/his)
Pediatrics
Seattle Children's Hospital/University of Washington
The introduction of highly effective modulator therapy (HEMT) has completely revolutionized the care of people with cystic fibrosis (CF). Improvements in many clinical outcomes—including lung function, nutrition and quality of life—have been seen since the initiation of HEMT. Less is known about the impacts of HEMT on pulmonary exacerbations (PEx) or the respiratory microbiology in people with CF. This workshop will discuss how the epidemiology around PEx events has changed in the current HEMT era, how HEMT impacts airway microbiology, and how CF providers think about PEx in people with CF on HEMT.
Speaker: Saumini Srinivasan, MD, MS – University of Tennessee College of Medicine
Speaker: Alexandra H. Toporek – Johns Hopkins University
Speaker: Majbritt Jeppesen, MD – Aarhus University Hospital
Speaker: Bryan S. Sherwood, PharmD – Dartmouth Health
Speaker: Andrew S. Purdy, PharmD – Indiana University Health